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Abstract
Background: Although considered an essential tool for monitoring the effect of combination antiretroviral treatment
(CART), HIV-1 RNA (viral load, VL) testing is greatly influenced by cost and availability of resources.
Objectives: To examine whether HIV infected patients who were initially successfully treated with CART have less frequent
monitoring of VL over time and whether CART failure and other HIV-disease and sociodemographic characteristics are
associated with less frequent VL testing.
Methods: The study included patients who started CART in the period 1999–2004, were older than 18 years, CART naive,
had two consecutive viral load measurements of ,400 copies/ml after 5 months of treatment and had continuous CART
during the first 15 months. The time between two consecutive visits (days) was the outcome and associated factors were
assessed using linear mixed models.
Results: We analyzed a total of 128 patients with 1683 visits through December 2009. CART failure was observed in 31 (24%)
patients. When adjusted for the follow-up time, the mean interval between two consecutive VL tests taken in patients
before CART failure (155.2 days) was almost identical to the interval taken in patients who did not fail CART (155.3 days). On
multivariable analysis, we found that the adjusted estimated time between visits was 150.9 days before 2003 and 177.6 in
2008/2009. A longer time between visits was observed in seafarers compared to non-seafarers; the mean difference was
30.7 days (95% CI, 14.0 to 47.4; p,0.001); and in individuals who lived more than 160 kilometers from the HIV treatment
center (mean difference, 16 days, p=0.010).
Conclusions: Less frequent monitoring of VL became common in recent years and was not associated with failure. We
identified seafarers as a population with special needs for CART monitoring and delivery.
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Introduction
Globally, monitoring of plasma HIV-1 RNA (viral load, VL)
and determination of CD4 cell counts is related to the strategy of
delivery of combination antiretroviral therapy (CART) and greatly
influenced by the cost and availability of resources. In the public
health approach of CART in resource-limited settings there is
currently no consensus on the type, frequency and cost
effectiveness of different types of monitoring (virological, immu-
nological or clinical). The open-label randomized DART trial
conducted in Uganda and Zimbabwe found 3% less mortality
after 5-years of follow-up in patients monitored with CD4 cell
counts every 3 months compared to patients with clinical
monitoring only [1]. In contrast, developed countries have an
individual approach to CART and assume that all antiretroviral
drugs and monitoring tools are available [2]. Croatia can be
considered a country with an individual approach to CART, but
has had a limited number of available antiretrovirals and the use of
monitoring tools were somewhat restricted mainly due to cost and
availability.
In developed countries, determination of plasma VL is
considered an essential component for monitoring effectiveness
of CART. The virological goal of CART is to achieve ,50 copies
of HIV-1 RNA per mililiter of plasma measured by polymerase
chain reaction (PCR) by week 24. Recommendations on the
frequency of VL testing after a patient achieves an undetectable
VL are mainly based on expert opinion and on the analysis of the
Eurosida cohort suggesting that patients who had a stable and fully
suppressive CART for 1 year had a low chance of experiencing
treatment failure in the ensuing months [3].
United States Department of Health and Human Services
(DHHS) [4] and international [5] guidelines suggest more frequent
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4 months). The current International AIDS Society-USA
guidelines state that once the VL is suppressed for a year and
CD4 cell counts are stable at 350/mL or greater, VL monitoring
can be extended for up to 6 months in patients with good
adherence [5].
It is also not clear when a VL test should be repeated after a
change in the CART regiment in a patient with fully suppressive
HIV-1 RNA. To assess the efficacy of the new regiment, the
DHHS guidelines recommend repeating a VL test 2 to 8 weeks
after a change in CART [4].
We examined whether there was a change in the frequency of
VL testing over time and calendar year in all HIV infected patients
in Croatia who started CART in the period 1999 to 2004.
Furthermore, we assessed different sociodemographic and HIV
disease factors related to the frequency of viral load testing.
Methods
Ethics statement
The study was approved by the Ethics Committee of the
University Hospital for Infectious Diseases (UHID), Zagreb,
Croatia. Written informed consent was obtained from all
participants.
Setting
Croatia has a centralized system of treatment and care for
patients with HIV infection and all patients are treated in Zagreb
at UHID. Also, antiretroviral drugs are only given from the
hospital pharmacy at UHID. Health insurance is universal and all
health care expenses including the cost of antiretrovirals and
monitoring are free of charge for the individual. Highly active
antiretroviral therapy became available through the national
health insurance scheme in April 1998. At the end of 1997
determination of HIV-1 RNA by PCR became available. Croatia
has a low-level epidemic; the epidemic started in 1985. The first
cases were identified among labor migrants who returned from
western European countries, and seafarers who acquired HIV in
Africa and Eastern Asia [2,6]. However, recent data suggest that a
concentrating epidemic among men who have sex with men is
emerging [7].
Since 1997, there is a comprehensive electronic database on
HIV infected patients available at UHID. We conducted a
retrospective cohort study on the frequency of VL monitoring in
population of patients on CART in Croatia from 1999 to 2009.
The total number of patients in care per calendar year ranged
from 120 in 1999 to 533 in 2009.
Inclusion and exclusion criteria and definitions
Inclusion criteria were the following: age 18 years old or older,
documented HIV-1 infection, initiation of CART at UHID from
1999 to 2004, and no active opportunistic disease at start of follow-
up. Participants had to have continuous CART during the first 15
months of treatment as judged by the pharmacy refill and an
undetectable VL (,400 copies/mL) on at least two consecutive
tests after 5 months of CART. We excluded patients who had been
treated at the time of acute HIV infection and had subsequently
discontinued CART.
We defined treatment failure as: a) two consecutive VL
measurements .400 copies/mL, with the earlier date defined as
the date of failure, b) a single VL measurement .10 000 copies/
mL, c) an AIDS-defining opportunistic infection or malignancy, or
d) death. Measurements after failure were not included in further
analysis. If the patient decided to stop therapy the visit before this
occurred was considered to be the last follow-up visit. The baseline
value for our analysis was the last measurement taken before the
15 months of treatment and the last follow up visit for patients who
did not fail was the last measurement taken before 31.12.2009.
Statistical methods
We used three outcome measures to assess the frequency of VL
testing. First, subjects were divided into those who had at least
50% of their measurements more than 5 months apart and those
who had not. Second, rates of VL measurements were computed
as the number of VL tests (numerator) divided by the person-time
contributed and rates are reported per one person-years of follow-
up. Third, we examined the time interval, defined as the number
of days between two consecutive VL tests for a subject. We than
examined how the frequency of VL testing is affected by age,
gender, type of initial CART, change in CART, duration of
treatment, follow-up time, calendar year, being employed as a
seafarer, distance from UHID, risk group and baseline and current
CD4 cell count. We also analyzed whether patients who failed had
less frequent VL testing prior to this event.
Baseline socio-demographic and clinical characteristics between
patients with at least half (50%) of their measurements more than 5
months apart and those with less than half (50%) of their
measurements more than 5 months apart were compared with chi
square tests for categorical variables and Wilcoxon rank sum tests
for continuous variables. We used Poisson analysis to compute the
rate of testing and rate ratios and associated 95% confidence
intervals (CI) for different baseline characteristics.
Longitudinal data analysis was initially explored graphically.
We then used a random coefficient model to take into account
repeated measures of the outcome (days between tests). Crude
analysis was performed including a random intercept and slope,
and one fixed or time-varying explanatory variable. Fixed
explanatory variables were gender, baseline age, HIV transmission
group, distance from HIV center, migrant work, level of
education, place of living (rural versus urban), baseline CD4 cell
count, clinical AIDS before CART, calendar year of CART
initiation, CART failure, having at least one CART change during
follow-up, type of initial CART and positive for hepatitis C
antibody. Time-varying covariates were type of current CART
regimen, current CD4 cell counts and the calendar year of VL
tests. Covariates with a p,0.25 in crude analysis were considered
as candidates for inclusion in the multivariable model. We
modeled follow-up time linearly and quadratically as fixed effects
in both crude and multivariable analysis. The linear value of
follow-up time was also specified as a random effect.
A p-value of 0.05 was considered significant. Analysis of
residuals revealed a number of outliers. When 47 outliers were
removed, type of CART regimen (nonnucleoside analogues versus
non-nonnucleoside analogues regimen) was not significant in
crude (p=0.071) nor in multivariable analysis (p=0.376), whereas
the interpretation of other coefficients did not change. We present
our models without removing outliers. We used SAS software
system release 9.1.3 (SAS Institute, Cary, NC) for all analyses.
Results
Baseline characteristics
A total of 175 patients 18 years of age or older started CART in
the period 1999 to 2004. One hundred twenty-eight (73%) met
our cohort inclusion criteria. We excluded 47 patients; 1 had HIV-
2 infection, 1 had an active illness during CART, 37 had
discontinuous CART in first 15 months of treatment, and 8 did
not have two consecutive VL ,400 copies/ml. Sociodemographic
Frequency of HIV-1 Viral Load Monitoring
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Table 1. The median age at baseline was 40 year (interquartile
range [IQR], 33 to 48). The majority of patients where male
(81%), had secondary education or less (65%) and lived more than
160 km from the treatment centre (55%). Sixteen (13%) were
seafarers. A total of 74 (58%) patients had more than 50% of VL
measurements less than 5 months apart and 54 (42%) patients had
not.
Antiretroviral failure and therapy
CART failure was observed in 31 (24%) patients. Of the 31
patients who failed, 3 died, 3 failed because of an AIDS event, 17
decided to stop CART and 8 were virological failures mainly
because of missing doses. All patients who stopped CART or had
other causes of virological failure achieved an undetectable VL
with a subsequent CART regimen. The median time to failure was
1.7 years (IQR, 0.7 to 2.8). Of 175 patients starting CART, 97
(55.4%) did not fail treatment.
At baseline, patients were equally likely to be treated with a non-
nucleoside reverse transcriptase inhibitor- (NNRTI; 62, 48%)
containing regimen and a protease inhibitor- (PI; 63, 50%)
containing regimen. Twenty percent used zidovudine (ZDV)+la-
mivudine (3TC)+efavirenz (EFV) at baseline, 20% ZDV+3TC+
ritonavir-boosted lopinivir (LPV/r) and 15% stavudine
(d4T)+3TC+EFV. Overall 65 (51%) patients changed their ART
regimen at least once; there were a total of 83 instances of CART
change. At last follow up, 23% were on ZDV+3TC+EFV, 17% on
abacavir (ABC)+3TC+EFV, 15% on ZDV+3TC+LPV/r; the
most frequent changes were d4T to ZDV (34%) and ZDV to ABC
(25%). The overall median time between a change in CART and
the following VL test was 90 days (IQR, 56 to 118).
Rate of testing
One hundred twenty-eight patients had 1555 follow-up visits
that contributed to a total of 632.7 person years of follow-up
through December 2009. The overall rate of viral load testing
was 2.5 per patient per year (95% confidence interval, 2.3 to
2.6). On bivariable analysis patients who lived 160 km or more
from UHID, were seafarers, were heterosexuals, did not fail
CART and had longer follow-up time, had fewer VL tests done
(Table 2).
Longitudinal data analysis
Longitudinal data analysis included a total of 1683 intervals
between successive tests. The median number of viral load tests
per individual was 12 (IQR 8, 16), the median length of follow-up
was 5.0 years (IQR 3.8, 6.7) and the median length of CART was
6.0 years (IQR 4.9, 7.7). The median of the median interval
between VL tests of each individual patient was 139.5 days (IQR,
117 to 172). Inspection of smoothed graphs of days between VL
tests and time, as well as the significant interaction of time*time,
suggested that time could be modeled both linear and quadratic.
Table 1. Comparison of baseline demographics and clinical characteristics according to frequency of viral load testing.
Frequency of viral load testing
Characteristics Total (n=128) Standard, n=74 Less frequent, n=54 P
Age, years 40.0 (33.0, 48.2) 39.7 (32.5, 48.7) 40.9 (35.1, 47.6) 0.710
Male 104 59 (80) 45 (83) 0.606
MSM 49 36 (49) 13 (24) 0.005
Distance from HIV center (.160 km) 70 30 (41) 40 (74) ,0.001
Migrant worker (seafarer) 16 3 (4) 13 (24) ,0.001
High school or lower education 83 44 (59) 39 (72) 0.135
Urban residence 83 47 (64) 36 (67) 0.712
Baseline CD4 count, cells/mL 276.0 (197.0, 432.5) 271.5 (187.0, 417.0) 296.5 (208.0, 457.0) 0.711
Baseline CD4 count ,200 cells/mL 33 22 (30) 11 (20) 0.232
Clinical AIDS before CART 44 26 (35) 18 (33) 0.832
CART initiation year
1999–2001 48 24 (32) 24 (44) 0.166
2002–2004 80 50 (68) 30 (56)
CART failure 31 24 (32) 7 (11) 0.011
Baseline CART
NNRT-based 62 34 (46) 28 (52) 0.661
PI-based 63 37 (50) 26 (48)
Had CART change on follow-up 65 40 (54) 25 (46) 0.386
Viral load before CART, log10 copies/ml 5.3 (4.8, 5.8) 5.2 (4.7, 5.7) 5.4 (4.9, 5.8) 0.307
CD4 cell count before CART, cells/mL 108.5 (25.0, 217.5) 89.5 (26.0, 193.0) 127.0 (24.0, 233.0) 0.216
Has hepatitis C antibody 16 5 (7) 11 (20) 0.021
Years of follow-up 5.0 (3.8–6.7) 4.4 (2.6, 6.1) 5.9 (4.3, 7.6) ,0.001
Standard, subjects having ,50% of measurements ,5 months apart. Less frequent, subjects having $50% of measurements .5 months apart.
Values are N (%) or median (interquartile range).
MSM, men who have sex with men; CART, combination antiretroviral therapy; NNRT, non nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
doi:10.1371/journal.pone.0015051.t001
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estimated mean interval between VL tests was 165 days at three
years of follow-up (corresponding to four years of CART).
In crude analysis patients who lived 160 km or more from the
HIV centre had a significantly greater estimated mean interval
between tests (164.2 days) than those who lived less than 160 km
Table 2. Rate of viral load tests per one year according to different baseline patients characteristics.
Characteristics N
No. of VL
tests/person years
Rate of
tests/one year Rate ratio P
Gender
Male 104 1282/526.7 2.4 (2.3, 2.6) 0.93 (0.81, 1.05) 0.249
Female 24 273/103.9 2.6 (2.3, 3.0)
Mode of infection
Sex between men 49 688/260.2 2.6 (2.5, 2.8) 1.12 (1.02, 1.25)
a 0.017
Heterosexual 56 598/262.7 2.3 (2.1, 2.5)
Intravenous drug use 9 106/41.2 2.6 (2.1, 3.1)
Other/Unknown 14 163/66.5 2.5 (2.1, 2.9)
Distance from HIV center
,160 km 58 710/259.9 2.7 (2.5, 2.9) 1.2 (1.08, 1.32) ,0.001
$160 km 70 845/370.6 2.3 (2.1, 2.4)
Migrant worker (seafarer)
Yes 16 163/88.1 1.9 (1.6, 2.2) 0.72 (0.61, 0.85) ,0.001
No 112 1392/542.5 2.6 (2.4, 2.7)
Level of education
High school and lower 83 991/409.0 2.4 (2.3, 2.6) 0.95 (0.86, 1.06) 0.351
College/University 45 564/221.6 2.5 (2.3, 2.8)
Place of living
Rural 45 508/203.3 2.5 (2.3, 2.7) 1.02 (0.92, 1.14) 0.720
Urban 83 1047/427.3 2.4 (2.3, 2.6)
CD4 cell count before CART
,200/mm
3 92 1129/451.1 2.5 (2.4, 2.7) 1.05 (0.94, 1.16) 0.350
$200/mm
3 36 426/179.5 2.4 (2.2, 2.6)
Years of follow-up
,4 39 232/84.5 2.7 (2.4, 3.1) 1.17 (1.01, 1.35) 0.040
4 to 5 43 525/207.2 2.5 (2.3, 2.8) 1.08 (0.96, 1.20) 0.192
$6 46 798/338.9 2.4 (2.2, 2.5) 1
Calendar year of CART initiation
1999–2001 48 674/278.6 2.4 (2.2, 2.6) 0.97 (0.87, 1.07) 0.511
2002–2004 80 881/352.1 2.5 (2.3, 2.7)
Clinical AIDS before CART
Yes 44 514/208.8 2.5 (2.3, 2.7) 1.00 (0.90–1.11) 0.966
No 84 1041/421.8 2.5 (2.3, 2.6)
CART failure
No 97 1369/567.3 2.4 (2.3, 2.5) 0.82 (0.70, 0.96) 0.012
Yes 31 186/63.3 2.9 (2.5, 3.4)
Baseline CART
NNRT-based 62 797/319.1 2.5 (2.3, 2.7) 1.04 (0.94, 1.15)
b 0.490
PI-based 63 730/302.8 2.4 (2.2, 2.6)
NNRT plus PI 2 24/7.4
NRT only 1 4/1.3
95% confidence intervals are in parenthesis.
aMen who had sex with men versus other categories.
bNNRT-based compared to PI-based.
VL, viral load; CART, combination antiretroviral therapy; NNRT, non-nucleoside reverse transcriptase inhibitor;
PI, protease inhibitor; NRT, nucleoside analogue reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0015051.t002
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(187.8 days) compared to non-seafarers (151.0 days, p,0.001)
(Table 3). Other variables associated with a longer number of
days between VL tests included not acquiring HIV through male
to male sex, having a higher current and baseline CD4 cell
count, treated in more recent years (2008/2009), having no
change in CART and not taking a CART regimen with two
nucleoside analogs and one NNRT (Table 3). CART failure was
not associated with a longer time between VL tests nor was
hepatitis C coinfection (Table 3). On multivariable analysis, the
distance from the HIV center, working as a seafarer and being
treated in years 2008/2009 were significantly associated with a
longer interval between VL tests (Table 4). Other HIV disease
factors (current CD4 cell count, type of CART regimen, having
a change in CART) were also associated with the interval
between VL testing, whereas transmission risk group was not
(Table 4).
Discussion
We found a substantial individual variation in the frequency of
VL testing in patients in Croatia. Less frequent testing among
patients on long-term CART became common in recent years.
Importantly, we did not observe that less frequent VL testing was
associated with an increase in CART failure. We found no
association of failure and time between VL testing on linear mixed
model analysis, which takes into account correlated measurements
on the same subject. The analysis of patients with less VL testing
compared to those with more frequent VL testing (Table 1) and
the analysis of number of tests per person-years (Table 2) actually
suggested that patients with more frequent VL testing were more
likely to have failed than patients with less frequent VL testing.
Risk factors for less frequent testing were living farther from the
treatment center and being employed as a seafarer. Both of these
factors likely represent patients’ difficulties in keeping scheduled
appointments due to distance, travel and working conditions.
Patients who had a change in their CART regimen were, on
average, more frequently monitored, however, this testing was
done after a substantially longer period (median, 90 days) than
recommendations from developed countries suggest. As expected,
the frequency of monitoring was influenced by the current CD4
cell count; patients with lower counts were monitored somewhat
more frequently. This effect was modest; our multivariable model
suggested an increase of time between tests of only 2.5 days per
100 cells.
Table 3. Relationship between baseline or time-varying
characteristics and interval (days) between viral load
measurements using crude mixed model analysis.
Crude analysis
a
Characteristics
Mean
interval,days
b
Estimate, days
(95% CI) P
Gender
Female 152.1 24.9 (213.2, 3.5) 0.251
Male 157 0
Age, per 10 years – 0.1 (25.9, 6.2) 0.933
Mode of infection
MSM 146.2 214.7 (227.3, 22.2) 0.022
Non-MSM 160.9 0
Distance from HIV center
,160 km 144.8 219.4 (231.5, 27.3) 0.002
$160 km 164.2 0
Migrant worker (seafarer)
No 151 236.8 (254.0, 219.6) ,0.001
Yes 187.8 0
Level of education
College/University 149.5 29.0 (222.0, 4.0) 0.173
High school and lower 158.5 0
Place of living
Rural 154.1 21.9 (215.1, 11.3) 0.776
Urban 156 0
Baseline CD4 cell
count/mL, per 100 cells
– 4.1 (0.6, 7.6) 0.022
Current CD4 cell
count/mL, per 100 cells
– 2.1 (0.4, 3.8) 0.018
Clinical AIDS before CART
No 156.1 2.4 (210.9, 15.6) 0.72
Yes 153.7 0
Calendar year of CART
initiation
1999–2001 153.2 23.2 (216.2, 9.8) 0.625
2002–2004 156.4 0
Patients who failed CART
No 155.3 0.1 (215.0, 15.1) 0.995
Yes 155.2 0
Had at least one CART change
No 161.8 12.8 (0.4, 25.2) 0.043
Yes 149 0
Type of initial CART
NNRT-based 152.3 27.7 (220.3, 5) 0.235
PI-based 160 0
Type of CART during follow-up
Non-NNRT 162.6 12.4 (2.4, 22.4) 0.015
NNRT-based 150.1 0
Calendar year
,2003 144 222.4 (240.2, 24.6) 0.014
2003–2005 149.2 217.2 (231.2, 23.2) 0.016
2006–2007 153.1 213.3 (223.1, 23.5) 0.008
2008–2009 166.4 0
Crude analysis
a
Characteristics
Mean
interval,days
b
Estimate, days
(95% CI) P
Positive for HCV antibody
Yes 163.7 29.7 (228.6, 9.2) 0.313
No 154.1 0
aAdjusted for the linear and quadratic term of time and one independent
variable.
bLeast square means estimates from the model. MSM, men who have sex with
men;
CART, combination antiretroviral therapy; NNRT, non nucleoside reverse
transcriptase inhibitor;
PI, protease inhibitor.
doi:10.1371/journal.pone.0015051.t003
Table 3. Cont.
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examining the frequency of VL testing [3,8,9,10,11,12]. Haubrich
et al. [8] conducted a randomized trial in the early CART era in
1996/97 to compare the outcome of frequent VL measurement
with infrequent VL measurement. They found that the frequent
group (VL tests every 2 months) had a better HIV-1 RNA
reduction at 6 months compared to infrequent group (VL tests
every 6 months). There was also a trend toward improved survival
in the frequent group. A retrospective analysis of clinical trials
conducted between 1992 and 1999 concluded that the interval
between study visits could not be safely increased because
significant numbers of drug toxicities would have been missed
[12]. The study population included many patients with low CD4
cell counts, patients who were treatment experienced and used
investigational drugs [12]. The analysis from Eurosida observa-
tional study concluded that a subset of patients such as those who
initially responded well to CART and are on a well tolerated and
durably fully suppressive CART can be monitored less frequently.
This conclusion was based on the low chance of experiencing
treatment failure in the next 3–6 months, not by assessing whether
the actual interval between tests is related to failure [3]. A recent
large observational study from Canada found a number of factors
related to the frequency of VL testing (geographic region, HIV risk
factor, age, year of CART initiation, type of CART regimen,
being in the first year of CART, AIDS-defining illness and
whether or not the previous VL was below the limit of detection)
[9]. This study population was different than ours; it included all
patients who started CART and not only those who were
considered adherent and had an initially successful CART
regimen. The median annual frequency of VL testing in this
population was 4.3 VL measurements per year. An earlier study
from Ontario, Canada found lower testing rates among injection
drug users, younger age and those residing in Toronto [10].
To our knowledge, factors associated with the frequency of VL
in middle income countries have as yet not been reported. Middle
income countries in southeastern Europe (Albania, Bosnia and
Herzegovina, Croatia, Kosovo, Macedonia, Montenegro, Serbia)
are not part of the European Union, have a low-level HIV
epidemic and have had difficulties in providing HIV/AIDS care
and CART. For example in Croatia in 2009, out of 26
antiretroviral formulations registered in the EU, 14 were available
to Croatian patients. There are also occasionally irregular supplies
Table 4. Relationship between baseline or time-varying characteristics and interval (days) between viral load measurements on
multivariable mixed model analysis
a.
Covariate Mean interval, days
b Estimate, days (95% CI) P
Intercept 172.7 ,0.001
Mode of infection
MSM 159.2 27.2 (218.7, 4.3) 0.219
Non-MSM 166.4 0
Distance from HIV center
,160 km 154.8 216.0 (228.2, -3.9) 0.010
$160 km 170.8 0
Migrant worker (seafarer)
No 147.5 230.7 (247.4, 214.0) ,0.001
Yes 178.2 0
Level of education
College/University 160.2 25.3 (216.5, 6.0) 0.356
High school and lower 165.4 0
Current CD4 cell count/mL, per 100 cells 2.5 (0.8, 4.2) 0.003
Had at least one CART change
No 169.2 12.8 (1.5, 24.2) 0.028
Yes 156.4 0
Type of CART during follow-up
NNRT-based 157.7 210.1 (219.3, 21.01) 0.030
c
Non-NNRT 167.9 0
Calendar year
,2003 150.9 226.7 (243.9, 29.3) 0.003
2003–2005 160.1 217.5 (231.3, 23.7) 0.013
2006–2007 162.6 214.9 (224.8, 25.1) 0.003
2008–2009 177.6 0
The intercept represents the average interval for a non-MSM who is a seafarer, lives $160 kilometers from Zagreb, has high school or lower education, has had at least
one CART change, is taking a non-NNRT regiment, has a CD4 cell count of 350 per mL, is treated in 2008/09 and has a follow-up time of 2 years.
aAdjusted for the linear and quadratic term of time.
bLeast square means estimates from the model.
cWhen 47 potential outlying observations were removed the result became insignificant (p=0.376).
MSM, men who have sex with men; CART, combination antiretroviral therapy; NNRT, non nucleoside reverse transcriptase inhibitor.
doi:10.1371/journal.pone.0015051.t004
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patients with HIV/AIDS is high [13,14]. Although there are not
many patients in need for treatment and the health care insurance
system is universal and free of charge for the individual, there is
pressure from health care authorities to save costs. Our findings
suggest that about 55% of patients who start CART can be safely
monitored with less frequent visits.
The aim of routine frequent VL testing in patients with
undetectable VL is to detect virological failure early, leading to
adherence interventions or early changes in therapy that will limit
ongoing viral replications and reduce the risk of accumulation of
resistance mutations. However, since failure was not preceded by
less frequent VL tests, our findings suggest that considerable
savings can be achieved by less frequent monitoring of stable
patients without compromising the efficacy of CART. On the
other hand one may argue that less frequent monitoring was
observed in our study mainly because patients who lived farther
from the HIV center and worked as seafarers had difficulties in
accessing facilities that perform VL testing.
Limitations
Our findings are subject to some limitations. First, this was not a
trial of frequency of VL testing, so we are unable to establish that
more or less frequent VL testing is causally associated with a
greater or lesser risk of CART failure. Although our data indicates
that less frequent testing is not associated with virological failure or
adverse HIV-related clinical outcomes this issue needs to be
further explored. Secondly, we included into the study only ART
naı ¨ve patients who were initially well suppressed and considered
fully adherent during the first 15 months of CART; the result
would have been different using the whole population receiving
CART. Thirdly, observational studies may be biased by not
including unmeasured confounders and we might have missed an
important predictor of less frequent VL testing. For example we
were not able to study employment status and income. However,
the magnitude of the differences we observed for our main
predictors (working as a seafarer and the distance from the HIV
center) makes it unlikely that an unmeasured confounder could
have altered these findings. Our patient registry is also highly
complete with little missing data, and we were able to include all
patients on CART in Croatia who met our inclusion criteria.
In conclusion, monitoring viral load became less frequent in
recent years in a population of patients who were initially
virologically well suppressed and considered adherent to CART.
Working as a seafarer was the most important sociodemographic
factor related to less frequent VL monitoring. Compared to
intervals in patients who did not fail, patients who failed CART
did not have longer times between VL monitoring visits before this
event occurred. Our findings support recent recommendations
that VL monitoring in adherent patients with a stable undetectable
VL can be extended to every 6 months. In our experience,
approximately 55% patients who start CART could be monitored
with less frequent visits.
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